<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1686" language="x-unspecified"/>
    <type:PFSMean xmi:id="13" sofa="6" begin="839" end="850"/>
    <type:PFSMean xmi:id="29" sofa="6" begin="1562" end="1573"/>
    <type:ORR xmi:id="17" sofa="6" begin="887" end="892"/>
    <type:ORR xmi:id="33" sofa="6" begin="1580" end="1585"/>
    <type:OSTime xmi:id="21" sofa="6" begin="1180" end="1188"/>
    <type:OSRate xmi:id="25" sofa="6" begin="1208" end="1213"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="In order to examine the efficacy and safety of nanoparticle albumin-bound&#13;&#10;paclitaxel (nab-P) in combination with bevacizumab (B) and gemcitabine (G) for&#13;&#10;the first-line treatment of patients with HER2-negative metastatic breast cancer &#13;&#10;(MBC). In this single-center, open-label phase II trial, patients with&#13;&#10;HER2-negative MBC received gemcitabine 1500 mg/m(2), nab-paclitaxel 150 mg/m(2), &#13;&#10;and bevacizumab 10 mg/kg (each administered intravenously) on days 1 and 15 of a &#13;&#10;28-day cycle. The primary end point was progression free survival (PFS);&#13;&#10;secondary end points were overall response rate (ORR), complete (CR) and partial &#13;&#10;(PR) response rates, clinical benefit (ORR + stable disease), overall survival&#13;&#10;(OS), and safety. Thirty patients were enrolled. One patient was ineligible and&#13;&#10;was not included in analysis. Median PFS was 10.4 months (95% CI: 5.6-15.2&#13;&#10;months). ORR was 75.9%, comprising eight (27.6%) CRs and 14 (48.3%) PRs; five&#13;&#10;patients had stable disease (SD) and two patients (6.9%) had progressive disease &#13;&#10;(PD) as their best response. The clinical benefit rate was 93.1% (27/29) in the&#13;&#10;overall group and 84.6% in the triple-negative cohort (11/13). The 18-month&#13;&#10;survival rate was 77.2% (95% CI: 51.1-90.5%). Eight (27.6%) patients experienced &#13;&#10;grade 3 or 4 toxicity: grade 4 neutropenic fever (n = 1) and grade 3 infection (n&#13;&#10;= 6), leukopenia, thrombocytopenia, peripheral neuropathy, seizure, shortness of &#13;&#10;breath, hematuria, and cardiac tamponade (one each). First-line therapy with&#13;&#10;nab-P, B, and G demonstrated a median PFS of 10.4 months and a 75.9% ORR with&#13;&#10;acceptable toxicity; this novel combination warrants investigation in a&#13;&#10;randomized study."/>
    <cas:View sofa="6" members="1 13 29 17 33 21 25"/>
</xmi:XMI>
